HC Wainwright reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $221.00 target price on the stock.
A number of other research firms have also recently issued reports on KRYS. Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Chardan Capital increased their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech presently has an average rating of "Buy" and a consensus price target of $215.83.
Check Out Our Latest Report on Krystal Biotech
Krystal Biotech Stock Up 2.0 %
Shares of KRYS stock traded up $3.39 during trading on Friday, hitting $175.22. The company had a trading volume of 302,138 shares, compared to its average volume of 266,264. The stock's 50-day moving average is $159.63 and its two-hundred day moving average is $174.93. The stock has a market capitalization of $5.05 billion, a price-to-earnings ratio of 58.60 and a beta of 0.87. Krystal Biotech has a 52 week low of $141.72 and a 52 week high of $219.34.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business's quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.30 EPS. On average, research analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.
Insider Buying and Selling at Krystal Biotech
In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company's stock.
Institutional Investors Weigh In On Krystal Biotech
Several institutional investors and hedge funds have recently bought and sold shares of KRYS. Entropy Technologies LP purchased a new position in shares of Krystal Biotech during the fourth quarter valued at approximately $548,000. Summit Trail Advisors LLC bought a new position in Krystal Biotech in the third quarter worth about $1,893,000. Swiss National Bank raised its stake in Krystal Biotech by 8.0% in the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock worth $7,117,000 after buying an additional 2,900 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in Krystal Biotech by 42.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock worth $8,239,000 after buying an additional 15,545 shares during the period. Finally, Citigroup Inc. boosted its position in Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company's stock valued at $6,386,000 after acquiring an additional 13,874 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
